ArticleActa psychiatrica Scandinavica2026
Use of Attention Deficit Hyperactivity Disorder Medication Among Danish Children and Adolescents From 2010 to 2023.
Article in Acta psychiatrica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionPharmacological treatment is an important component in the multimodal management of attention deficit hyperactivity disorder (ADHD), but contemporary trends in ADHD medication use among boys and girls in Denmark have not been fully characterized. This study aimed to provide an updated and detailed description of ADHD medication use among Danish children and adolescents during 2010-2023.
methodsWe analyzed filled prescriptions for ADHD medication in youths aged 5-17 years in Denmark (2010-2023), calculating incidence rates, prevalence proportions, male/female ratios, treatment persistence, age at initiation, and prescriber setting. Analyses were stratified by sex and age.
resultsThe incidence rates of ADHD medication use followed a u-shaped pattern for boys, declining from 0.59 per 100 person-years in 2010 to 0.34 in 2014, before rising to 1.0 in 2023. Among girls, incidence rates increased continuously from 0.20 per 100 person-years in 2010 to 0.67 per 100 person-years in 2023. Prevalence proportions were stable until 2018, where an increase was observed for both sexes, reaching 3.4% for boys and 1.8% for girls in 2023. The male/female incidence and prevalence ratios decreased consistently from 2010 to 2023. ADHD medication was initiated at a median age of 13 years for girls and 11 years for boys. The share of index prescriptions from child and adolescent psychiatry increased, reaching 87% in 2023. Most 5-9-year-olds (65%) and almost half of 10-13-year-olds (45%) were covered by an ADHD medication prescription 5 years after treatment initiation, as opposed to 29% of 14-17-year-olds.
conclusionADHD medication use in Denmark increased from 2010 to 2023, particularly among girls, where the prevalence tripled compared to a 1.5-fold increase in boys. This likely reflects greater awareness of ADHD in girls, although their 2-year treatment delay compared to boys warrants clinical attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.